Cure for CLL - Derivates of para-NO-ASA for the treatment of CLL

Ref.-Nr. 4045

Despite considerable improvement of therapeutic strategies in the last decade, CLL remains incurable by conventional chemoimmuno-therapies. The development of new treatment options remains an important goal. The present invention provides compounds acting as an effective and selective medicament for the treatment of neoplastic diseases or proliferative disorders, in particular compounds which induce selectively apoptosis of degenerated cells providing reduced side effects in living organisms. The compounds of the present invention are characterized by a high selectivity towards neoplastic cells. CLL cells show a higher sensitivity towards the compounds than PBMCs opening a therapeutic window. The EC50 for CLL cells is in the lower micromolar range. Furthermore, compounds have proven activity on different CLL populations. The activity against CLL cells has been shown in a xenograft model of CLL. It has been shown that compounds may be suitable for the treatment of other neoplasias.

Vorteile

  • Compound claims towards novel derivatives of para-NO-ASA: High selectivity, high activity, tested on different CLL cell populations, proven in a xenograft model of CLL
  • Development team comprising chemists and clinicians
  • Compounds may be suitable for the treatment of other neoplasias

Kommerzielle Anwendung

On behalf of the University of Cologne, we are offering this opportunity for licensing.

Aktueller Stand

A PCT application is pending.

Relevante Veröffentlichungen

Gehrke I et al.: Ther Adv Hematol. 2011 Oct;2(5):279-89.

Razavi R et al.: Clin Cancer Res. 2011 Jan 15;17(2):286-93.

Eine Erfindung der Uni Köln.

Dr. Andreas Wagener

aw@provendis.info
+49 208 9410538